1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Mr D Redfern
|
|||
b)
|
Position/status
|
Chief Strategy Officer
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 9 July 2020, on Ordinary Shares
held within an ISA.
|
|||
c)
|
Price(s) and
volume(s)
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
||
|
£15.9271
|
25
|
|
||
|
|
|
|
||
d)
|
Aggregated information
Aggregated volume
Price
|
N/A (single transaction)
|
|||
e)
|
Date
of the transaction
|
2020-07-10
|
|||
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
a)
|
Name
|
Ms V Whyte
|
|||
b)
|
Position/status
|
Company Secretary
|
|||
c)
|
Initial
notification/amendment
|
Initial notification
|
|||
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
a)
|
Name
|
GlaxoSmithKline plc
|
|||
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
a)
|
Description of the financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|||
b)
|
Nature of the transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 9 July 2020, on Ordinary Shares
held within an ISA.
|
|||
c)
|
Price(s) and
volume(s)
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
||
|
£15.9271
|
21
|
|
||
|
|
|
|
||
d)
|
Aggregated information
Aggregated volume
Price
|
N/A (single transaction)
|
|||
e)
|
Date
of the transaction
|
2020-07-10
|
|||
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: July
13, 2020
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|